| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/31/2000 | WO2000050641A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 08/31/2000 | WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | WO2000050562A2 Dna encoding snorf25 receptor |
| 08/31/2000 | WO2000050453A1 A novel inhibitor of programmed cell death |
| 08/31/2000 | WO2000050429A1 Drugs containing phosphoric acid derivatives as the active ingredient |
| 08/31/2000 | WO2000050408A1 Pyridazin-3-one derivatives and medicines containing the same |
| 08/31/2000 | WO2000050400A1 2-aminopyridines containing fused ring substituents |
| 08/31/2000 | WO2000050068A2 Elastin-based compositions |
| 08/31/2000 | WO2000050029A1 Seam soft capsule preparations containing dihydrobenzofuran derivative |
| 08/31/2000 | WO2000050017A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| 08/31/2000 | WO2000033667A3 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants |
| 08/31/2000 | WO2000029003A3 Method for preventing and reversing atherosclerosis in mammals |
| 08/31/2000 | WO2000025805A8 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
| 08/31/2000 | WO2000023472A3 Interferon-beta fusion proteins and uses |
| 08/31/2000 | WO2000021548A3 Angiogenically effective unit dose of fgf and method of administering |
| 08/31/2000 | WO2000012074A3 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| 08/31/2000 | WO2000001375A3 Calcium channel blockers |
| 08/31/2000 | DE10008042A1 Neurokinin-1-Rezeptorantagonisten Neurokinin-1 receptor antagonists |
| 08/31/2000 | CA2363621A1 A novel inhibitor of programmed cell death |
| 08/31/2000 | CA2362906A1 Dna encoding snorf25 receptor |
| 08/31/2000 | CA2362548A1 Elastin-based compositions |
| 08/31/2000 | CA2362533A1 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | CA2362099A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 08/31/2000 | CA2333955A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| 08/30/2000 | EP1031349A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| 08/30/2000 | EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers |
| 08/30/2000 | EP1030919A2 Cdk2 protein and cdk2 protein complexes |
| 08/30/2000 | EP1030916A2 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis |
| 08/30/2000 | EP1030915A1 A novel gene and uses therefor |
| 08/30/2000 | EP1030857A2 Adenosine a1 receptor agonists |
| 08/30/2000 | EP1030856A2 Adenosine a1 receptor agonists |
| 08/30/2000 | EP1030851A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030840A1 Cyclic amine derivatives and their use as drugs |
| 08/30/2000 | EP1030836A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030835A2 Urea derivatives and their use as integrin inhibitors |
| 08/30/2000 | EP1030834A1 Benzocycloheptene derivatives |
| 08/30/2000 | EP1030831A1 Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides |
| 08/30/2000 | EP1030682A1 Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor |
| 08/30/2000 | EP1030679A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
| 08/30/2000 | EP1030673A1 Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis |
| 08/30/2000 | EP1030665A1 Therapeutic uses of quinoline derivatives |
| 08/30/2000 | EP1030661A1 N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA 2? INHIBITORS |
| 08/30/2000 | EP1030651A1 Novel oral dosage form for carvedilol |
| 08/30/2000 | EP0799198B1 Anti-inflammatory compounds |
| 08/30/2000 | EP0765328B1 Pirydyl imidazole derivatives and processes for the preparation thereof |
| 08/30/2000 | EP0584290B1 Endothelin antagonists |
| 08/30/2000 | EP0248819B2 Recombinant fibroblast growth factors |
| 08/30/2000 | CN1265141A Use of lactobacillus for reduction of fibrinogen level in blood |
| 08/30/2000 | CN1265109A Thiazolobenzoheterocycles, prepn. and medicines containing same |
| 08/30/2000 | CN1265102A Benzothia (oxa) diazol derivatives and their use as endothelin-receptor antagonists |
| 08/30/2000 | CN1265033A Certain diarylimidaozle derivatives, new class of NPY speific ligands |
| 08/30/2000 | CN1055920C Aklyl benzoylguanidines derivatives |
| 08/30/2000 | CN1055919C Arylbenzoylguanidin |
| 08/30/2000 | CN1055859C Application of stilbene compound and its derivative in prepn. of endothelium element antagonist agent |
| 08/30/2000 | CN1055852C Wine for reducing blood-pressure |
| 08/30/2000 | CN1055844C Erigeron breviscapus freezed-drying agent for injection,and its prepn. process |
| 08/30/2000 | CN1055840C Prepn. for treating coronary hart disease |
| 08/29/2000 | US6111094 Enhanced antisense modulation of ICAM-1 |
| 08/29/2000 | US6111084 Sialyl lewis mimetics produced by solid phase synthesis; antiinflammatory agents |
| 08/29/2000 | US6111076 Human G-protein coupled receptor (HIBCD07) |
| 08/29/2000 | US6110964 For treating arthritis, inflammatory bowel disease, crohn's disease, emphysema, acute respiratory distress syndrome, asthma chronic obstructive pulmonary disease, alzheimer's disease, organ transplant toxicity, cachexia, cancer |
| 08/29/2000 | US6110952 Preventing or treating nasal congestion, otitis media and sinusitis without undesired side effects, also asthma, pain, migraine, substance abuse and addiction, gastrointestinal disorder, ulcer, stomach hyperacidity |
| 08/29/2000 | US6110940 Salts of an anti-migraine indole derivative |
| 08/29/2000 | US6110939 As a substance p antagonists treating tachykinin-mediated disease, asthma, central nervous system disorder |
| 08/29/2000 | US6110933 Amino acid derivatives and their use as phospholipase A2 inhibitor |
| 08/29/2000 | US6110932 Increase the level of endogenous growth hormone for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, accelerating wound healing |
| 08/29/2000 | US6110927 Treatment of atrial fibrillation |
| 08/29/2000 | US6110920 Treatment of cardiovascular disorders and impotency |
| 08/29/2000 | US6110909 Squalene synthetase inhibiting antilipemic agents |
| 08/29/2000 | US6110903 Benzimidazole inhibitors of fructose 1,6-bisphosphatase |
| 08/29/2000 | US6110747 Compounds and methods for modulating tissue permeability |
| 08/29/2000 | US6110721 Isolated polypeptide at least about 80% homologous to and possesses at least one immune epitope of thrombin reference amino acid sequence; anticoagulants and procoagulants; diagnosis of blood disorders; drug screening; antitumor agents |
| 08/29/2000 | US6110701 DNA encoding precursor of interleukin-1β converting enzyme--related cysteine proteinase II (ICErel -II) |
| 08/29/2000 | US6110688 Separating compounds from human urine; freezing human urine, thawing urine, separating precipitate by centrifuging, recovering precipitate, dissolvingin solution, dialysis, separating supernatant, isolate protein, detect with antibody |
| 08/29/2000 | US6110460 Methods of using morphogen analogs |
| 08/29/2000 | US6110459 Grafting of myocardium tissues |
| 08/24/2000 | WO2000049144A2 Pyk2 binding proteins |
| 08/24/2000 | WO2000049135A2 Substrate for cell growth |
| 08/24/2000 | WO2000049043A2 Human lipid-associated proteins |
| 08/24/2000 | WO2000049015A1 Pyridine compounds and their pharmaceutical use |
| 08/24/2000 | WO2000049014A1 Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate |
| 08/24/2000 | WO2000048996A2 β-ALANINE DERIVATIVES |
| 08/24/2000 | WO2000048992A1 Acylated aminoacetonitriles as cysteine protease inhibitors |
| 08/24/2000 | WO2000048989A1 Mevinolin derivatives |
| 08/24/2000 | WO2000048987A1 Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines |
| 08/24/2000 | WO2000048643A1 Biodegradable, injectable oligomer-polymer composition |
| 08/24/2000 | WO2000048625A2 Inhibitors for use in hemostasis and immune function |
| 08/24/2000 | WO2000048608A1 Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside rb¿1? |
| 08/24/2000 | WO2000048606A1 Compositions and methods for use in targeting vascular destruction |
| 08/24/2000 | WO2000048603A1 DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS |
| 08/24/2000 | WO2000048602A1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 08/24/2000 | WO2000048601A1 Medicament for treating hypertension |
| 08/24/2000 | WO2000048595A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen |
| 08/24/2000 | WO2000048592A1 Essential fatty acids in the prevention of cardiovascular events |
| 08/24/2000 | WO2000048591A1 Combinations for the treatment of diseases involving angiogenesis |
| 08/24/2000 | WO2000048590A1 Substituted stilbene compounds with vascular damaging activity |
| 08/24/2000 | WO2000048571A1 Spontaneously dispersible n-benzoyl staurosporine compositions |
| 08/24/2000 | WO2000031051B1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 08/24/2000 | WO2000027380A3 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |